Intra-Cellular Therapies Past Earnings Performance
Past criteria checks 0/6
Intra-Cellular Therapies has been growing earnings at an average annual rate of 5.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 63.9% per year.
Key information
5.8%
Earnings growth rate
15.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 63.9% |
| Return on equity | -7.5% |
| Net Margin | -14.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
Dec 09Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Revenue & Expenses Breakdown
How Intra-Cellular Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 614 | -86 | 471 | 0 |
| 30 Jun 24 | 565 | -84 | 445 | 0 |
| 31 Mar 24 | 514 | -111 | 424 | 0 |
| 31 Dec 23 | 464 | -140 | 410 | 0 |
| 30 Sep 23 | 420 | -155 | 400 | 0 |
| 30 Jun 23 | 366 | -184 | 383 | 0 |
| 31 Mar 23 | 311 | -228 | 382 | 0 |
| 31 Dec 22 | 250 | -256 | 359 | 0 |
| 30 Sep 22 | 188 | -298 | 344 | 0 |
| 30 Jun 22 | 138 | -321 | 326 | 0 |
| 31 Mar 22 | 103 | -304 | 295 | 0 |
| 31 Dec 21 | 84 | -284 | 273 | 0 |
| 30 Sep 21 | 71 | -259 | 251 | 0 |
| 30 Jun 21 | 56 | -237 | 233 | 0 |
| 31 Mar 21 | 38 | -232 | 205 | 0 |
| 31 Dec 20 | 23 | -227 | 186 | 0 |
| 30 Sep 20 | 10 | -207 | 151 | 0 |
| 30 Jun 20 | 3 | -187 | 113 | 0 |
| 31 Mar 20 | 1 | -160 | 87 | 0 |
| 31 Dec 19 | 0 | -148 | 65 | 0 |
| 30 Sep 19 | 0 | -148 | 51 | 0 |
| 30 Jun 19 | 0 | -155 | 44 | 0 |
| 31 Mar 19 | 0 | -154 | 35 | 0 |
| 31 Dec 18 | 0 | -155 | 30 | 0 |
| 30 Sep 18 | 0 | -145 | 27 | 0 |
| 30 Jun 18 | 0 | -126 | 24 | 0 |
| 31 Mar 18 | 0 | -106 | 24 | 0 |
| 31 Dec 17 | 0 | -98 | 24 | 0 |
| 30 Sep 17 | 0 | -95 | 25 | 0 |
| 30 Jun 17 | 0 | -102 | 26 | 0 |
| 31 Mar 17 | 0 | -116 | 26 | 0 |
| 31 Dec 16 | 0 | -116 | 25 | 0 |
| 30 Sep 16 | 0 | -118 | 24 | 0 |
| 30 Jun 16 | 0 | -120 | 22 | 0 |
| 31 Mar 16 | 0 | -110 | 19 | 0 |
| 31 Dec 15 | 0 | -105 | 18 | 0 |
| 30 Sep 15 | 0 | -91 | 15 | 0 |
| 30 Jun 15 | 0 | -65 | 14 | 0 |
| 31 Mar 15 | 0 | -48 | 12 | 0 |
| 31 Dec 14 | 1 | -31 | 10 | 0 |
| 30 Sep 14 | 1 | -24 | 9 | 0 |
| 30 Jun 14 | 2 | -22 | 8 | 0 |
| 31 Mar 14 | 2 | -26 | 7 | 0 |
| 31 Dec 13 | 3 | -27 | 6 | 0 |
Quality Earnings: ITCI is currently unprofitable.
Growing Profit Margin: ITCI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ITCI is unprofitable, but has reduced losses over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ITCI has a negative Return on Equity (-7.54%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 23:02 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intra-Cellular Therapies, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Jason Matthew Gerberry | BofA Global Research |